Hybridoma cell line, cd68 monoclonal antibody, preparation method and application
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- 富恩生物技术(成都)有限公司
- Publication Date
- 2021-10-29
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to the field of biomedical technology, and more specifically, relates to a hybridoma cell line capable of producing CD68 monoclonal antibody, CD68 monoclonal antibody, and the preparation method and application of the antibody. Background technique
[0002] CD68 is a 110KDa glycoprotein associated with lysosomal granules. CD68 is a marker of macrophages in many human tissues, including bone marrow, spleen, intestinal lamina propria and alveoli. Peripheral blood monocytes are also positive, while bone marrow precursors and peripheral blood granulocytes can also be studied. In recent years, it has been reported in the literature that CD68 can also be used as a marker of histiocytes, mainly for the study of macrophages, acute and chronic myeloid leukemia, and tumors derived from histiocytes such as malignant fibrous histiocytoma.
[0003] With the deepening of tumor immunology research, it is known that the cells infiltrati...